Action of copper(II) complex with ß-diketone and 1,10-phenanthroline (CBP-01) on sarcoma cells and biological effects under cell death
Polloni, Lorena; Silva, Ana Carolina de Seni; Teixeira, Samuel Cota; Azevedo, Fernanda Van Petten de Vasconcelos; Zóia, Mariana Alves Pereira; Silva, Marcelo Santos da; Lima, Paula Marynella Alves Pereira; Correia, Lucas Ian Veloso; Almeida, Janaina do Couto; Silva, Cláudio Vieira da; Ávila, Veridiana de Melo Rodrigues; Goulart, Luiz Ricardo Filho; Morelli, Sandra; Guerra, Wendell; Oliveira Júnior, Robson José de.
Biomed Pharmacother
; 112: 108586, 2019.
Artículo
en Inglés
| SES-SP, SESSP-IBPROD, SES-SP | ID: but-ib15833
This work reports the biological evaluation of a copper complex of the type [Cu(O–O)(N–N)ClO4], in whichO–O = 4,4,4-trifluoro-1-phenyl-1,3-butanedione (Hbta) and N–N = 1,10-phenanthroline (phen), whose genericname is CBP-01. The cytotoxic effect of CBP-01 was evaluated by resazurin assay and cell proliferation wasdetermined by MTT assay. DNA fragmentation was analyzed by gel electrophoresis. Cell cycle progression wasdetected through propidium iodide (PI) staining. Apoptosis and autophagy were determined by, respectively,Annexin V and 7-AAD staining and monodansylcadaverine (MDC) staining. The changes in intracellular reactiveoxygen species levels were detected by DCFDA analysis. The copper complex CBP-01 showed in vitro antitumoractivity with IC50s values of 7.4µM against Sarcoma 180 and 26.4 against murine myoblast cells, displayingselectivity toward the tumor cell tested in vitro (SI > 3). An increase in reactive oxygen species (ROS) gen-eration was observed, which may be related to the action mechanism of the complex. The complex CBP-01 mayinduce DNA damage leading cells to accumulate at G0/G1 checkpoint where, apparently, cells that are not ableto recover from the damage are driven to cell death. Evidence has shown that cell death is initiated by autophagydysfunction, culminating in apoptosis induction. The search for new metal-based drugs is focused on overcomingthe drawbacks of already used agents such as acquired resistance and non-specificity; thus, the results obtainedwith CBP-01 show promising effects on cancer cells.
Biblioteca responsable:
BR78.1
Ubicación: BR78.1
Texto completo
Documentos relacionados